多發性骨髓瘤市場規模、佔有率、成長分析、按藥物類別、按治療方法、按分銷管道、按地區 - 行業預測，2024-2031

2022年全球多發性骨髓瘤市場規模將為219.8億美元，從2023年的253億美元成長到2031年的779.3億美元，在預測期間（2024-2031年）預計將以複合年成長率成長。 2018 年為15.1%）。

由於人們對這種主要影響漿細胞的罕見血癌的認知不斷提高和發病率不斷上升，多發性骨髓瘤市場正在經歷巨大的發展勢頭。隨著新療法的不斷出現，競爭格局正在不斷變化，市場參與企業的治療專業知識也顯著提高。根據Globocan 2020數據等報告，全球新診斷癌症患者人數為19,292,789人，癌症相關死亡人數約1,000萬人。國際癌症研究機構 (IARC) 預測，到 2031 年，這一數字將上升至 2,750 萬例新病例和 1,630 萬人死亡，其中男性面臨的風險是女性的 1.5 倍。主要風險因素包括吸煙和飲酒等生活方式的選擇，以及男性肥胖率高。血癌盛行率的增加以及對醫療基礎設施、研究和治療方案的需求不斷增加，推動了市場的成長。然而，全球多發性骨髓瘤市場的擴張在一定程度上受到開發中國家低治療率的限制。目前，隨著醫療保健產業致力於應對這項挑戰，美國多發性骨髓瘤市場預計將在未來幾年保持永續的年複合成長率（CAGR）。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 次要/一級資訊來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 價值鏈分析
• 原料分析
• 價格分析
• 消費行為分析
• PESTEL分析

多發性骨髓瘤市場：依藥物類別

• 市場概況
• 蛋白酶體抑制劑
• 免疫調節劑
• 單株抗體
• 類固醇

多發性骨髓瘤市場：依治療方法

• 市場概況
• 免疫療法
• 化療
• 放射治療
• 幹細胞移植

多發性骨髓瘤市場：按分銷管道

• 市場概況
• 醫院
• 零售
• 網路藥房

多發性骨髓瘤市場規模：按地區

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Bristol-Myers Squibb Company（US）
• Amgen Inc.（US）
• Johnson & Johnson（Janssen Pharmaceuticals）（US）
• Novartis AG（Switzerland）
• Sanofi（France）
• Takeda Pharmaceutical Company Limited（Japan）
• Pfizer Inc.（US）
• Celgene Corporation（Bristol-Myers Squibb Company）（US）
• AbbVie Inc.（US）
• Genentech, Inc.（F. Hoffmann-La Roche Ltd）（US）
• Karyopharm Therapeutics（US）
• Teva Pharmaceutical Industries Ltd.（Israel）
• ONO Pharmaceutical Co., Ltd.（Japan）
• Merck & Co., Inc.（US）
• Eli Lilly and Company（US）
• GlaxoSmithKline plc（UK）
• Bayer AG（Germany）
• Takeda Oncology（Millennium Pharmaceuticals）（Japan）
• Oncopeptides AB（Sweden）
• Bluebird Bio, Inc.（US）

Global Multiple Myeloma Market size was valued at USD 21.98 billion in 2022 and is poised to grow from USD 25.30 billion in 2023 to USD 77.93 billion by 2031, growing at a CAGR of 15.1% in the forecast period (2024-2031).

The multiple myeloma market is experiencing significant momentum driven by increasing awareness and rising incidence of this rare blood cancer, primarily affecting plasma cells. As new therapeutics continue to emerge, the competitive landscape is evolving, with a marked uptick in treatment expertise among leading market participants. Reports, such as the Globocan 2020 data, highlight a staggering 19,292,789 new cancer diagnoses worldwide, alongside nearly 10 million cancer-related fatalities. The International Agency for Research on Cancer (IARC) projects that these numbers will escalate to 27.5 million new cases and 16.3 million deaths by 2031, with men facing a 1.5-fold higher risk than women. Key risk factors include lifestyle choices like smoking, alcohol use, and higher obesity rates among men, while the disease predominantly affects older adults, particularly those aged 55 to 65. Contributing to market growth is the increasing incidence of hematological cancers and a growing demand for healthcare infrastructure, research, and treatment options. However, the proliferation of the global multiple myeloma market is somewhat curtailed by low treatment rates in developing nations. As it stands, the US multiple myeloma market is anticipated to maintain a sustainable compound annual growth rate (CAGR) in the forthcoming years, as the healthcare sector intensifies its focus on combating this challenging disease.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Myeloma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiple Myeloma Market Segmental Analysis

Global Multiple Myeloma Market is segmented on the drug class, therapy, distribution channel, and region. By drug class, market is segmented into Proteasome Inhibitors, Immunomodulatory Drugs, Monoclonal Antibodies, and Steroids. By therapy, market is segmented into immunotherapy, chemotherapy, radiation therapy, and stem cell transplant. By distribution channel, market is segmented into hospital, retail, and online pharmacies. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Multiple Myeloma Market

The global multiple myeloma market is significantly driven by the increasing adoption of monoclonal antibodies, which are heralded for their high safety profile and targeted action against myeloma cells. Advances in nanomedicine and microRNA therapies, alongside the ongoing development of effective and safe treatments, are further propelling market growth. The integration of monoclonal antibodies, like Darzalex and Empliciti, with existing therapies enhances treatment efficacy, attracting clinician preference. Additionally, the rising incidence of hematological cancers, particularly multiple myeloma linked to specific genetic mutations, coupled with an aging population and rising healthcare costs, are amplifying the demand for innovative treatment solutions within this market.

Restraints in the Global Multiple Myeloma Market

The global multiple myeloma market is significantly restrained by low treatment rates in emerging nations, primarily driven by the high cost of treatments, which limits patient access. Furthermore, the scarcity of skilled healthcare professionals and inadequate healthcare infrastructure in these regions compound the issue, hindering effective diagnosis and treatment. The COVID-19 pandemic has exacerbated this situation, resulting in a notable decline in clinical visits and heightened reluctance among patients to seek medical care. Additionally, a pervasive lack of public awareness regarding multiple myeloma remains a critical barrier, ultimately impeding the market's growth potential throughout the forecast period.

Market Trends of the Global Multiple Myeloma Market

The global multiple myeloma market is experiencing a significant upward trend driven by increased research and development activities. This surge is fostering the introduction of novel therapies, evidenced by a rise in drug approvals and market entries, particularly in monoclonal antibodies like Darzalex and Empliciti. These advancements not only offer innovative treatment options, extending relapse intervals for patients, but also complement traditional therapies such as Revlimid and Velcade. Additionally, the emergence of second-generation proteasome inhibitors like Ninlaro and Kyprolis further diversifies treatment strategies, enhancing patient outcomes and solidifying the market's growth trajectory in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree Of Competition
• Top Investment Pockets
• Ecosystem Of the Market
• Value Chain Analysis
• Raw Material Analysis
• Pricing Analysis
• Consumer Behaviour Analysis
• PESTEL Analysis

Multiple Myeloma Market, By Drug Class

• Market Overview
• Proteasome Inhibitors
• Immunomodulatory Drugs
• Monoclonal Antibodies
• Steroids

Multiple Myeloma Market, By Therapy

• Market Overview
• Immunotherapy
• Chemotherapy
• Radiation Therapy
• Stem Cell Transplant

Multiple Myeloma Market, By Distribution Channel

• Market Overview
• Hospital
• Retail
• Online Pharmacies

Multiple Myeloma Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Janssen Pharmaceuticals) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (Bristol-Myers Squibb Company) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (F. Hoffmann-La Roche Ltd) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ONO Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Oncology (Millennium Pharmaceuticals) (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncopeptides AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments